The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Liraglutide and Renal Outcomes in Type 2 Diabetes
Open accessAbstract
BACKGROUND: In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted in lower risks of the primary end point (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) and death. However, the long-term effects of liraglutide on renal outcomes in patients with type 2 diabetes are unknown. METHODS: We report the prespecified secondary renal outcomes of that randomized, controlled trial in which patients were assigned to receive liraglutide or placebo. The secondary renal outcome was a composite of new-onset persistent macroalbuminuria, persistent doubling of the serum creatinine level, end-stage renal disease, or death due to renal disease. The risk of renal outcomes was determined with the use of time-to-event analyses with an intention-to-treat approach. Changes in the estimated glomerular filtration rate and albuminuria were also analyzed. RESULTS: A total of 9340 patients underwent randomization, and the median follow-up of the patients was 3.84 years. The renal outcome occurred in fewer participants in the liraglutide group than in the placebo group (268 of 4668 patients vs. 337 of 4672; hazard ratio, 0.78; 95% confidence interval [CI], 0.67 to 0.92; P=0.003). This result was driven primarily by the new onset of persistent macroalbuminuria, which occurred in fewer participants in the liraglutide group than in the placebo group (161 vs. 215 patients; hazard ratio, 0.74; 95% CI, 0.60 to 0.91; P=0.004). The rates of renal adverse events were similar in the liraglutide group and the placebo group (15.1 events and 16.5 events per 1000 patient-years), including the rate of acute kidney injury (7.1 and 6.2 events per 1000 patient-years, respectively). CONCLUSIONS: This prespecified secondary analysis shows that, when added to usual care, liraglutide resulted in lower rates of the development and progression of diabetic kidney disease than placebo. (Funded by Novo Nordisk and the National Institutes of Health; LEADER ClinicalTrials.gov number, NCT01179048 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The LEADER and REWIND trials also report a greater than 20% reduction in the risk of developing new macroalbuminuria, along with favourable trends in other clinically relevant adverse renal outcomes. 26,27”
The cited source says what the claim attributes to it.
In the citing paper
“Glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) have also been shown to improve kidney outcomes (95-100).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [97]
The cited source says what the claim attributes to it.
In the citing paper
“GLP-1 RAs have also been shown to improve kidney outcomes (104-109).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [106]
In the citing paper
“However, the composite kidney outcomes in these trials were evaluated as secondary outcomes, and the reported effects were largely driven by a lower risk of new-onset macroalbuminuria. 23-25”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [24]
In the citing paper
“Treatment with these drugs is in fact associated with a reduced decline in the estimated glomerular filtration rate (eGFR), as well as with a reduction in urinary albumin excretion and in the incidence rate of de novo albuminuria [28,29].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [28]
In the citing paper
“However, these benefits were driven by a lower risk of persistent macroalbuminuria [6,10,13].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationEffects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citationStevens, P. E., Levin, A., & for the Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members* (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-11-201306040-00007 · Cited by 3,607
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Assessing Kidney Function — Measured and Estimated Glomerular Filtration Rate
Stevens, L. A., Coresh, J., Greene, T., & Levey, A. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra054415 · Cited by 2,952
Flagged first, then by citations
1 of the 32 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 501–600 of 1,000
Liljedahl, L., Pedersen, M. H., McGuire, J. N., & James, P. (2019) · Physiological Reports · doi:10.14814/phy2.13994 · Cited by 21
Liraglutide Improves Renal Endothelial Function in Obese Zucker Rats on a High-Salt Diet
Sukumaran, V., Tsuchimochi, H., Sonobe, T., Shirai, M., & Pearson, J. T. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.254821 · Cited by 21
Store-operated calcium entry: Pivotal roles in renal physiology and pathophysiology
Chaudhari, S. K., Mallet, R. T., Shotorbani, P. Y., Tao, Y., & Ma, R. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370220975207 · Cited by 21
Apperloo, E. M., Cherney, D. Z. I., Kuhlman, A. B., Mann, J. F. E., Rasmussen, S., Rossing, P., Tuttle, K. R., Vrhnjak, B., & Heerspink, H. J. L. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae150 · Cited by 20
Self-citationSiddiqui, H. F., Ali, D., Sajid, M., Qureshi, S., Siddiqui, H., Hasan, A., Ripley, D. P., Ahmed, R., & Waqas, S. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70123 · Cited by 20
Zhu, H., Yang, B., Lu, L., Li, Y., Sui, R., Liu, K., Tan, S., Wang, L., Qiu, J., Zhong, J., et al. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.5684 · Cited by 20
Liraglutide Improves the Kidney Function in a Murine Model of Chronic Kidney Disease
Ougaard, M. K., Sembach, F. E., Jensen, H. E., Pyke, C., Knudsen, L. B., & Kvist, P. H. (2020) · The Nephron journals/Nephron journals · doi:10.1159/000509418 · Cited by 20
Dekkers, I. A., Bizino, M. B., Paiman, E. H. M., Smit, J. W. A., Jazet, I. M., de Vries, A. P. J., & Lamb, H. J. (2020) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2020.09.006 · Cited by 20
He, F., Chen, W., Xu, W., Liu, D., Xiao, Z., Tang, Y., Lin, Z., Liao, Y., Bin, J., Chen, G., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14908 · Cited by 20
Bouchi, R., Kondo, T., Ohta, Y., Goto, A., Tanaka, D., Satoh, H., Yabe, D., Nishimura, R., Harada, N., Kamiya, H., et al. (2022) · Diabetology International · doi:10.1007/s13340-022-00605-x · Cited by 20
Yanai, H., Katsuyama, H., Hakoshima, M., & Adachi, H. (2023) · Biomedicines · doi:10.3390/biomedicines11020567 · Cited by 20
Wang, J., Wang, Y., Wang, Y., Li, Y., Zhang, J., Zhang, H., Fu, X., Guo, Z., Yang, Y., Kang, K., et al. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13405 · Cited by 20
The GLP-1-mediated gut-kidney cross talk in humans: mechanistic insight
Hinrichs, G. R., Hovind, P. H., & Asmar, A. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00476.2023 · Cited by 20
Which Patients with Obesity Are at Risk for Renal Disease?
Sandino, J., Luzardo, L., Morales, E., & Praga, M. (2021) · The Nephron journals/Nephron journals · doi:10.1159/000513868 · Cited by 20
The role of anti-obesity medication in prevention of diabetes and its complications
Oh, T. J. (2019) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes.2019.28.3.158 · Cited by 19
“…or macroalbuminuria, new or worsening CKD, doubling of serum creatinine, ESRD, renal transplant, or renal death HR, 0.87 (95% CI, 0.79–0.96; P= 0.006) Mann et al. (2017)49 Liraglutide Composite of new persistent macroalbuminuria, persistent doubling of serum creatinine, ESRD, or renal death HR,…”
BackgroundInfluentialTargeting NF-κB in diabetic nephropathy: exploring the therapeutic potential of phytoconstituents
Abhirami, B. L., Krishna, A. A., Kumaran, A., & Chiu, C. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01555-z · Cited by 19
Rodent models of diabetic kidney disease: human translatability and preclinical validity
Sembach, F. E., Østergaard, M. V., Vrang, N., Feldt‐Rasmussen, B., Fosgerau, K., Jelsing, J., & Fink, L. N. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.05.004 · Cited by 19
Management of Kidney Failure in Patients with Diabetes Mellitus: What Are the Best Options?
Buades, J. M., Craver, L., y Pino, M. D. D. P., Prieto‐Velasco, M., Ruiz, J. C., Salgueira, M., de Sequera, P., & Vega, N. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132943 · Cited by 19
Fan, D., Wang, Y., Liu, B., & Yin, F. (2022) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000807 · Cited by 19
Bouchi, R., Kondo, T., Ohta, Y., Goto, A., Tanaka, D., Satoh, H., Yabe, D., Nishimura, R., Harada, N., Kamiya, H., et al. (2024) · Diabetology International · doi:10.1007/s13340-024-00723-8 · Cited by 19
Effects of Diabetes Medications Targeting the Incretin System on the Kidney
MacIsaac, R. J., & Thomas, M. C. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10380917 · Cited by 19
Chen, Z., Zhou, Q., Liu, C., Zeng, Y., & Yuan, S. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.49690 · Cited by 19
Chazova, I. E., Shestakova, M. V., Zhernakova, Y. V., Blinova, N. V., Маркова, Т. Н., Mazurina, N. V., Владиславович, Е. М., Tereshchenko, S. N., Жиров, И. В., Komarov, A. L., et al. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-2-6-61 · Cited by 19
Obesity-Related Glomerulopathy: Clinical Management
Herman‐Edelstein, M., Weinstein, T., & Chagnac, A. (2021) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2021.06.007 · Cited by 19
Liu, X., Patel, K. P., & Zheng, H. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.022542 · Cited by 19
Kidney function assessment and endpoint ascertainment in clinical trials
Khan, M. S., Bakris, G. L., Packer, M., Shahid, I., Anker, S. D., Fonarow, G. C., Wanner, C., Weir, M. R., Zannad, F. M., & Butler, J. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab832 · Cited by 19
Donate‐Correa, J., Sánchez-Niño, M. D., González-Luis, A., Ferri, C. M., Martín-Olivera, A., Martín‐Núñez, E., Fernández‐Fernández, B., Tagua, V. G., Fernández, C. M., Ortíz, A., et al. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac143 · Cited by 19
Diabetes management before, during, and after bariatric and metabolic surgery
Kheniser, K. G., & Kashyap, S. R. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.06.006 · Cited by 19
Kalayci, A., Januzzi, J. L., Mitsunami, M., Tanboga, I. H., Karabay, C. Y., & Gibson, C. M. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf037 · Cited by 18
Adamczak, M., Kurnatowska, I., Naumnik, B., Stompór, T. P., Tylicki, L., & Krajewska, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312941 · Cited by 18
GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease
Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01036-y · Cited by 18
Niessner, A., Tamargo, J. L., Koller, L., Saely, C. H., Schmidt, T. A., Savarese, G., Waßmann, S., Rosano, G. M. C., Ceconi, C., Torp-Pedersen, C. T., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx625 · Cited by 18
Hubbard, D. M., Colantonio, L. D., Rosenson, R. S., Brown, T. M., Jackson, E. A., Huang, L., Orroth, K. K., Reading, S. R., Woodward, M., Bittner, V., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01247-0 · Cited by 18
Microalbuminuria Constitutes a Clinical Action Item for Clinicians in 2021
Rossing, P., & Epstein, M. (2021) · The American Journal of Medicine · doi:10.1016/j.amjmed.2021.11.019 · Cited by 18
Premature Death in Kidney Transplant Recipients: The Time for Trials is Now
Vinson, A. J., Singh, S., Chadban, S., Cherney, D., Gaber, A. O., Gill, J. S., Helgeson, E., Herzog, C. A., Jardine, M., Jha, V., et al. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021111517 · Cited by 18
Suzuki, T., Sato, T., Tanaka, M., Endo, K., Nakata, K., Ogawa, T., Hosaka, I., Akiyama, Y., Umetsu, A., & Furuhashi, M. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108779 · Cited by 18
Sohn, M., Nam, S., Nauck, M. A., & Lim, S. K. (2024) · BMC Medicine · doi:10.1186/s12916-024-03483-z · Cited by 18
Gregg, L. P., Richardson, P. A., Nambi, V., Petersen, L. A., Matheny, M. E., Virani, S. S., & Navaneethan, S. D. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000477 · Cited by 18
Folestad, E. B., Mehlem, A., Ning, F. C., Oosterveld, T., Palombo, I., Singh, J., Olauson, H., Witasp, A., Thorell, A., Stenvinkel, P., et al. (2024) · Kidney International · doi:10.1016/j.kint.2024.11.026 · Cited by 18
New Agents for the Treatment of Type 2 Diabetes
Libianto, R., & Ekinci, E. I. (2019) · Critical Care Clinics · doi:10.1016/j.ccc.2018.11.007 · Cited by 18
Omics research in diabetic kidney disease: new biomarker dimensions and new understandings?
Tofte, N., Persson, F., & Rossing, P. R. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00759-4 · Cited by 18
Li, K., Sun, J., Huang, N., Ma, Y., Han, F., Liu, Y., Hou, N., & Sun, X. (2020) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13391 · Cited by 18
LDL-Cholesterol versus Glucose in Microvascular and Macrovascular Disease
Emanuelsson, F., & Benn, M. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa242 · Cited by 18
Elnaem, M. H., Mansour, N. O., Nahas, A. R. F., Baraka, M. A., Elkalmi, R. M., & Cheema, E. U. (2020) · International Journal of General Medicine · doi:10.2147/ijgm.s285191 · Cited by 18
Role of Glucose Metabolism and Mitochondrial Function in Diabetic Kidney Disease
Stanton, R. C. (2021) · Current Diabetes Reports · doi:10.1007/s11892-020-01372-2 · Cited by 18
Goderis, G., Vaes, B., Mamouris, P., Craeyveld, E. V., & Mathieu, C. (2021) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1508-3912 · Cited by 18
Tommerdahl, K. L., Kendrick, J., Nelson, R. G., & Bjornstad, P. (2022) · Clinical Science · doi:10.1042/cs20210627 · Cited by 18
Hypertension mediated kidney and cardiovascular damage and risk stratification: Redefining concepts
Márquez, D. F., Rodríguez‐Sánchez, E., Segura, J., Ruilope, L. M., & Ruiz‐Hurtado, G. (2022) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2021.10.008 · Cited by 18
Mohammadi‐Shemirani, P., Sjaarda, J., Gerstein, H. C., Treleaven, D. J., Walsh, M. W., Mann, J. F. E., McQueen, M., Hess, S., & Paré, G. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2018.291104 · Cited by 18
Self-citationVarin, E. M., McLean, B. A., & Lovshin, J. A. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.08.011 · Cited by 17
Cardiorenal interactions in heart failure: insights from recent therapeutic advances
Damman, K., & Testani, J. M. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad096 · Cited by 17
Incretin and glucagon receptor polypharmacology in chronic kidney disease
McFarlin, B. E., Duffin, K. L., & Konkar, A. A. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00374.2023 · Cited by 17
Jhu, J., Fang, Y., Huang, C., Liou, H., Chen, M., & Tsai, M. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14361 · Cited by 17
Redouane, B., Greene, S. J., Fudim, M., Vaduganathan, M., Ambrosy, A. P., Sun, J., DeVore, A. D., McNulty, S. E., Mentz, R. J., Hernandez, A. F., et al. (2020) · Circulation Heart Failure · doi:10.1161/circheartfailure.119.006758 · Cited by 17
Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies
Williams, D. M., & Evans, M. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00917-8 · Cited by 17
Seetharaman, R., Pawar, S. R., & Advani, M. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15100 · Cited by 17
Woo, V. C., Connelly, K. A., Lin, P., & McFarlane, P. A. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1576479 · Cited by 17
Activation of the renal GLP‐1R leads to expression of Ren1 in the renal vascular tree
Bjørnholm, K. D., Ougaard, M. E., Skovsted, G. F., Knudsen, L. B., & Pyke, C. (2021) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.234 · Cited by 16
Novel GLP-1 analog supaglutide improves glucose homeostasis in diabetic monkeys
Cui, Q., Liao, Y., Jiang, Y., Huang, X., Tao, W., Zhou, Q., Shao, A., Zhao, Y., Li, J., Ma, A., et al. (2020) · Journal of Endocrinology · doi:10.1530/joe-20-0255 · Cited by 16
Diagnosis and treatment of post-cholecystectomy diarrhoea
Huang, R.-L., Huang, W.-K., Xiao, X.-Y., Ma, L., Gu, H.-Z.-R., & Yang, G. (2023) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v15.i11.2398 · Cited by 16
Mima, A., KIDOOKA, S., NAKAMOTO, T., KIDO, S., Gotoda, H., Lee, R., Murakami, A., & Lee, S. (2023) · In Vivo · doi:10.21873/invivo.13440 · Cited by 16
Narrative review of the effects of antidiabetic drugs on albuminuria
Yaribeygi, H., Atkin, S. L., Katsiki, N., & Sahebkar, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27503 · Cited by 16
Tsai, S., & Chen, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133152 · Cited by 16
Sumida, Y., Yoneda, M., Toyoda, H., Yasuda, S., Tada, T., Hayashi, H., Nishigaki, Y., Suzuki, Y., Naiki, T., Morishita, A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144939 · Cited by 16
Opportunities of Antidiabetic Drugs in Cardiovascular Medicine
Yan, C., Thijs, L., Cao, Y., Trenson, S., Zhang, Z., Janssens, S. P., Staessen, J. A., & Feng, Y. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.14791 · Cited by 16
Sridhar, V. S., Dubrofsky, L., Boulet, J., & Cherney, D. Z. I. (2020) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2020-0100 · Cited by 16
Monitoring and management of hyperglycemia in patients with advanced diabetic kidney disease
Escott, G. M., da Silveira, L. G., Cancelier, V. D. A., Dall’Agnol, A., & Silveiro, S. P. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107774 · Cited by 16
Glucagon-like Peptide-1 Receptor Agonists
Jeon, J. Y., & Kim, H. J. (2021) · Stroke revisited · doi:10.1007/978-981-16-5123-6_14 · Cited by 16
Damianaki, A., Polychronopoulou, E., Wuerzner, G., & Burnier, M. (2021) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-021-00495-1 · Cited by 16
Martin, W. P., Nair, M., Chuah, Y. H. D., Malmodin, D., Pedersen, A., Abrahamsson, S., Hutter, M., Abdelaal, M., Elliott, J. A., Fearon, N. M., et al. (2022) · Clinical Science · doi:10.1042/cs20220205 · Cited by 16
Renal Proximal Tubular Cells: A New Site for Targeted Delivery Therapy of Diabetic Kidney Disease
Li, H., Dai, W., Liu, Z., & He, L. (2022) · Pharmaceuticals · doi:10.3390/ph15121494 · Cited by 16
New Glucose-Lowering Agents for Diabetic Kidney Disease
de Vos, L. C., Hettige, T., & Cooper, M. E. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2018.01.002 · Cited by 16
Dulaglutide and renal protection in type 2 diabetes
Cherney, D. Z. I., Verma, S., & Parker, J. D. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30125-6 · Cited by 16
Cardiovascular Effects of Liraglutide
Mikhail, N. E. (2018) · Current Hypertension Reviews · doi:10.2174/1573402114666180507152620 · Cited by 16
Personalized Management of Type 2 Diabetes
Peter, P. R., & Lupsa, B. C. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1244-0 · Cited by 16
Liraglutide for the Treatment of Type 2 Diabetes and Safety in Diabetic Kidney Disease
Cherney, D. Z. I., & Tuttle, K. R. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01260120 · Cited by 16
Women and diabetes: preventing heart disease in a new era of therapies
Galati, G., Sabouret, P., Germanova, O., & Bhatt, D. L. (2021) · European Cardiology Review · doi:10.15420/ecr.2021.22 · Cited by 15
Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes
Mosenzon, O., Schechter, M., & Leibowitz, G. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.04.005 · Cited by 15
Suzuki, Y., Kaneko, H., Nagasawa, H., Okada, A., Fujiu, K., Jo, T., Takeda, N., Morita, H., Nishiyama, A., Gohda, T., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15561 · Cited by 15
DONALD, E. M., Driggin, E., Choe, J. Y., Batra, J., Vargas, F., Lindekens, J., Fried, J., Raikhelkar, J., Bae, D. J., Oh, K. T., et al. (2024) · Clinical Transplantation · doi:10.1111/ctr.15401 · Cited by 15
Myeloid-derived growth factor in diseases: structure, function and mechanisms
Chen, P., Huang, X., Li, W., Wen, W., Cao, Y., Li, J., Huang, Y., & Hu, Y. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00874-z · Cited by 15
Effect of linagliptin on oxidative stress markers in patients with type 2 diabetes: a pilot study
Makino, H., Matsuo, M., Hishida, A., Koezuka, R., Tochiya, M., Ohata, Y., Tamanaha, T., Son, C., Miyamoto, Y., & Hosoda, K. (2018) · Diabetology International · doi:10.1007/s13340-018-0376-9 · Cited by 15
Martínez, J. J. G. (2019) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2019.03.005 · Cited by 15
Pioneering oral peptide therapy for patients with type 2 diabetes
Nauck, M. A., & Meier, J. J. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30182-2 · Cited by 15
Olufade, T. O., Jiang, L., Israni, R., Huang, J., & Gosmanov, A. R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14530 · Cited by 15
Ferrari, F., Scheffel, R. S., Martins, V. M., Santos, R. D., & Stein, R. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00515-4 · Cited by 15
Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection
Yau, K., Odutayo, A., Dash, S., & Cherney, D. Z. I. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.07.007 · Cited by 15
Packer, M. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13191 · Cited by 15
Doggrell, S. A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1519547 · Cited by 15
Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice?
Eckel, R. H., Farooki, A., Henry, R. R., Koch, G. G., & Leiter, L. A. (2019) · Clinical Diabetes · doi:10.2337/cd19-0001 · Cited by 15
Huang, L., Ma, R., Lin, T., Chaudhari, S. K., Shotorbani, P. Y., Yang, L., & Wu, P. (2019) · Experimental Biology and Medicine · doi:10.1177/1535370219876531 · Cited by 15
Idzerda, N. M. A., Clegg, L. E., Hernandez, A. F., Bakris, G. L., Penland, R. C., Boulton, D. W., Bethel, M. A., Holman, R. R., & Heerspink, H. J. L. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13958 · Cited by 15
Patoulias, D., Katsimardou, A., Kalogirou, M., Zografou, I., Toumpourleka, M., Imprialos, K. P., Stavropoulos, K., Stergiou, I., Papadopoulos, C. E., & Doumas, M. N. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.04.001 · Cited by 15
Hasanzad, M., Sarhangi, N., Nikfar, S., Ostad, S. N., & Meybodi, H. R. A. (2020) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-020-00619-9 · Cited by 15
OX-HDL: A Starring Role in Cardiorenal Syndrome and the Effects of Heme Oxygenase-1 Intervention
Peterson, S. J., Choudhary, A., Kalsi, A., Zhao, S., Alex, R., & Abraham, N. G. (2020) · Diagnostics · doi:10.3390/diagnostics10110976 · Cited by 15
Sridhar, V. S., Ambinathan, J. P. N., Gillard, P., Mathieu, C., Cherney, D. Z. I., Lytvyn, Y., & Singh, S. K. (2021) · Transplantation · doi:10.1097/tp.0000000000003919 · Cited by 15
Al‐Ozairi, E., Irshad, M., Alkandari, J., SOJAN, L. G., Alroudhan, D., Alotaibi, N., & le Roux, C. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70172 · Cited by 14
Standl, E., & Schnell, O. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108054 · Cited by 14
Kawai, Y., Sankoda, A., Waki, K., Miyake, K., Hayashi, A., Mieno, M., Wakui, H., Tsurutani, Y., Saito, J., Hirawa, N., et al. (2021) · JMIR Research Protocols · doi:10.2196/31061 · Cited by 14
Metadata
- Authors
- Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., & Buse, J. B.
- Affiliations
- Mount Sinai Hospital (CA)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-08-31
- Volume
- 377
- Issue
- 9
- Pages
- 839-848
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2752707491
- Semantic Scholar
- e3932087f500b455476965939bdced15360eb028
- Cited by
- 1,253
- References
- 32
- Citations by year
- 2026: 99 · 2025: 116 · 2024: 121 · 2023: 131 · 2022: 134 · 2021: 161 · 2020: 180 · 2019: 139 · 2018: 152 · 2017: 20
- FWCI
- 106.07
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Americanae (AECID Library) (publishedVersion, other-oa)
- ResearchOnline - JCU (James Cook University) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, other-oa)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-sa)
- Funders
- Novo Nordisk
- National Institutes of Health (UL1TR001111)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- liraglutide, type 2 diabetes, renal outcomes, diabetic nephropathy, macroalbuminuria, end-stage renal disease, acute kidney injury, glucagon-like peptide-1 analogues, albuminuria, estimated glomerular filtration rate, cardiovascular risk, renal adverse effects, LEADER trial, cardiovascular outcomes, serum creatinine doubling, usual care
- MeSH terms
- Liraglutide, Aged, Albuminuria, Creatinine, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Follow-Up Studies, Glomerular Filtration Rate, Humans, Hypoglycemic Agents, Kidney Failure, Chronic, Male, Middle Aged, Glucagon-Like Peptide 1, Intention to Treat Analysis, Acute Kidney Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
